Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol.
1 other identifier
interventional
444
1 country
56
Brief Summary
Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma. This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly. The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Jun 2000
Longer than P75 for phase_3
56 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2000
CompletedFirst Submitted
Initial submission to the registry
May 2, 2002
CompletedFirst Posted
Study publicly available on registry
May 3, 2002
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2004
CompletedSeptember 19, 2016
September 1, 2016
May 2, 2002
September 16, 2016
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Confirmation of non-small cell bronchogenic carcinoma (epidermoid, squamous, adeno, large cell anaplastic carcinoma, but no small cell or carcinoid) must be histologically or cytologically confirmed.
- No prior antineoplastic chemotherapy, hormonal therapy or therapy with biological response modifiers
- No previous irradiation to the only area of measurable disease.
You may not qualify if:
- Past or current history of neoplasm other than the entry diagnosis. Exceptions are curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or other cancers treated by surgery or radiation with a disease free survival longer than 5 years.
- Patients who have undergone surgery less than 3 weeks prior to enrollment.
- History of serious cardiac disease not adequately controlled.
- Patients with serious active infections or other serious underlying medical condition.
- Uncontrolled diabetes mellitis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (56)
Genesis Cancer Center
Hot Springs, Arkansas, 71913, United States
Little Rock Hematology/Oncology Associates
Little Rock, Arkansas, 72205, United States
Highlands Oncology Group
Springdale, Arkansas, 72764, United States
Medical Oncology Care Associates
Orange, California, 92868, United States
Naval Medical Center
San Diego, California, 92134, United States
Danbury Hospital/Praxair Cancer Center
Danbury, Connecticut, 06810, United States
Walter Reed Army Hospital
Washington D.C., District of Columbia, 20307, United States
Washington VA Medical Center
Washington D.C., District of Columbia, 20422, United States
Good Samaritan Medical Center
West Palm Beach, Florida, 33401, United States
Wellstar Cobb Hospital
Austell, Georgia, 30060, United States
Joliet Oncology/Hematology Associates,Ltd.
Joliet, Illinois, 60435, United States
Mid Illinois Hematology and Oncology Associates, Ltd.
Normal, Illinois, 61761, United States
West Suburban Center for Cancer Care
River Forest, Illinois, 60305, United States
Community Cancer Care, Inc.
Indianapolis, Indiana, 46202, United States
Associated Physicians & Surgeons Clinic, LLC
Terre Haute, Indiana, 47804, United States
Mercy Cancer Center
Mason City, Iowa, 50401, United States
Siouxland Hematology/Oncology Associates
Sioux City, Iowa, 51101, United States
Jewish Medical Plaza
Louisville, Kentucky, 40202, United States
University of Louisville
Louisville, Kentucky, 40202, United States
Louisiana Oncology Associates
Lafayette, Louisiana, 70506, United States
Louisiana State University Health Sciences Center
Shreveport, Louisiana, 71130, United States
Maine General Medical Center
Waterville, Maine, 04901, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Hematology and Oncology Associates of Southern Michigan,P.C
Jackson, Michigan, 49201, United States
Hennepin County Medical Center
Minneapolis, Minnesota, 55415, United States
Fairview-University Medical Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
Metro Minnesota CCOP
Saint Louis Park, Minnesota, 55416, United States
Ellis Fischel Cancer Center
Columbia, Missouri, 65203, United States
Creighton University Cancer Center
Omaha, Nebraska, 68131, United States
The Center for Cancer and Hematologic Disease
Cherry Hill, New Jersey, 08003, United States
Hematology-Oncology of Central New Jersey
Red Bank, New Jersey, 07701, United States
Community Medical Center
Toms River, New Jersey, 08755, United States
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109, United States
Advanced Oncology Associates
Armonk, New York, 10504, United States
Brooklyn VA
Brooklyn, New York, 11209, United States
Maimonides Medical Center
Brooklyn, New York, 11209, United States
Clifton Springs Hospital and Clinic
Clifton Springs, New York, 14432, United States
Goshen Medical Associates
Goshen, New York, 10924, United States
New York Oncology-Hematology,P.C./Capital District Hematology, Oncology Associates
Latham, New York, 12110, United States
Hematology/Oncology of Rockland
New York, New York, United States
Upstate New York Cancer R & E
Rochester, New York, 14623, United States
Raleigh Hematology Associates, Wake Practice
Cary, North Carolina, 27609, United States
Quadrangle Medical Specialists, Southern Oncology Research
Greenville, North Carolina, 27834, United States
Mid Dakota Clinic
Bismarck, North Dakota, 58501, United States
Columbus CCOP
Columbus, Ohio, 43206, United States
Central Pennsylvania Hematology & Medical Oncology Associates, P.C.
Lemoyne, Pennsylvania, 17043, United States
Albert Einstein Healthcare Network
Philadelphia, Pennsylvania, 19141, United States
University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213, United States
Guthrie Clinic Ltd
Sayre, Pennsylvania, 18840, United States
Boston Cancer Group, PLC
Memphis, Tennessee, 38104, United States
Don & Sybil Harrington Cancer Center
Amarillo, Texas, 79106, United States
Brackenridge Hospital
Austin, Texas, 78701, United States
Southwest Regional Cancer Center
Austin, Texas, 78705, United States
Southwest Cancer Center
Lubbock, Texas, 79415, United States
Northwest Medical Specialties, PLLC
Tacoma, Washington, 98405, United States
Madigan Army Medical Center
Tacoma, Washington, 98431, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 2, 2002
First Posted
May 3, 2002
Study Start
June 1, 2000
Study Completion
December 1, 2004
Last Updated
September 19, 2016
Record last verified: 2016-09